Global Cancer Nanomedicine Market Outlook 2022
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Over the past several years, many innovative and revolutionary techniques have been developed in order to treat cancer. These techniques range from basic surgical removal to X-ray irradiation to system wide flooding with anticancer agents. However, each of these approaches has its own series of undesirable side effects that are both dangerous and damaging to the overall health of the patient. On the contrary, recent breakthroughs in nanomedicine have managed to change all that. Now at last there is hope for a cure that is effective and can be made it safe.
Use of nanomedicines for cancer is one of the largest and most evolving segments containing multiple products in both market and clinical pipeline. Nanotechnology based liposome products could be observed as one of the most advance segment among oncology medicines. For instance, Doxil by Ortho pharmaceuticals was among first approved cancer nanomedicines by US FDA in 1995 for treating AIDS-related Kaposi’s sarcoma. DaunoXome by Galen Ltd is also a liposomal formulation used for the treatment of HIV relates Kaposi sarcoma and clinical trials for utilization of this medicine for leukemia is also under investigation. More products are at different stages of clinical trials which will be introduced in global market in coming years.
Nanoparticles are easily absorbed by cells due to smaller size and investigators used this property in disease diagnosis. Oncologists can get better idea of tumor shape and size along with exact location for better treatment. In market few nanoparticle based imaging agents are presents which are used for Magnetic Resonance (MR) imaging. For instance, Endorem by Guerbet, Resovist by Bayer and Feridex by Berlex Laboratories are SPIO nanoparticles commonly used for imaging. Besides oncology, they are also used in cardiovascular and cerebral disease diagnoses which also have mature market. Use of these nanoparticles in ultrasound based imaging has been proposed by investigators. This market has less competition and few products which gives significant opportunities to tap this segment. New products are expected to enter in this segment in coming years due to which its size is expected to increase several folds in future.
The future of cancer nanotechnology lies on a multifunctional nanoplatform that combines both therapeutic components and multimodality imaging. The ultimate goal is that multifunctional nanomedicine works as efficient, targeted in vivo drug delivery without systemic toxicity, and the dose delivered as well as the therapeutic efficacy can be accurately measured noninvasively with time. In the future, nanotechnology could possibly be strategically implemented in new developing drug delivery systems which could lead to significant expansion in the drug markets. These new drug delivery methods are likely to provide the appropriate platform for the pharmaceutical companies to reformulate their existing drugs in the market. This would in turn lead to extending the life of their products and ensuring an improved performance of drugs by increasing effectiveness, safety and patient adherence, and ultimately reducing healthcare costs.
“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
Over the past several years, many innovative and revolutionary techniques have been developed in order to treat cancer. These techniques range from basic surgical removal to X-ray irradiation to system wide flooding with anticancer agents. However, each of these approaches has its own series of undesirable side effects that are both dangerous and damaging to the overall health of the patient. On the contrary, recent breakthroughs in nanomedicine have managed to change all that. Now at last there is hope for a cure that is effective and can be made it safe.
Use of nanomedicines for cancer is one of the largest and most evolving segments containing multiple products in both market and clinical pipeline. Nanotechnology based liposome products could be observed as one of the most advance segment among oncology medicines. For instance, Doxil by Ortho pharmaceuticals was among first approved cancer nanomedicines by US FDA in 1995 for treating AIDS-related Kaposi’s sarcoma. DaunoXome by Galen Ltd is also a liposomal formulation used for the treatment of HIV relates Kaposi sarcoma and clinical trials for utilization of this medicine for leukemia is also under investigation. More products are at different stages of clinical trials which will be introduced in global market in coming years.
Nanoparticles are easily absorbed by cells due to smaller size and investigators used this property in disease diagnosis. Oncologists can get better idea of tumor shape and size along with exact location for better treatment. In market few nanoparticle based imaging agents are presents which are used for Magnetic Resonance (MR) imaging. For instance, Endorem by Guerbet, Resovist by Bayer and Feridex by Berlex Laboratories are SPIO nanoparticles commonly used for imaging. Besides oncology, they are also used in cardiovascular and cerebral disease diagnoses which also have mature market. Use of these nanoparticles in ultrasound based imaging has been proposed by investigators. This market has less competition and few products which gives significant opportunities to tap this segment. New products are expected to enter in this segment in coming years due to which its size is expected to increase several folds in future.
The future of cancer nanotechnology lies on a multifunctional nanoplatform that combines both therapeutic components and multimodality imaging. The ultimate goal is that multifunctional nanomedicine works as efficient, targeted in vivo drug delivery without systemic toxicity, and the dose delivered as well as the therapeutic efficacy can be accurately measured noninvasively with time. In the future, nanotechnology could possibly be strategically implemented in new developing drug delivery systems which could lead to significant expansion in the drug markets. These new drug delivery methods are likely to provide the appropriate platform for the pharmaceutical companies to reformulate their existing drugs in the market. This would in turn lead to extending the life of their products and ensuring an improved performance of drugs by increasing effectiveness, safety and patient adherence, and ultimately reducing healthcare costs.
“Global Cancer Nanomedicine Market Outlook 2022” Report Highlights:
- Overview & Mechanism of Action of Nanomedicine
- Nanomedicine Engineering: Design & Strategy
- Cancer Nanomedicine as Diagnostic & Therapeutics Tool
- Global Cancer Nanomedicine Market Overview & Dynamics
- Global Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase
- Global Cancer Nanomedicine Clinical Pipeline: 124 Drug
- Marketed Cancer Nanomedicine: 8 Drugs
1. CANCER NANOMEDICINE: AN OPTIMISTIC AVENUE
1.1 Introduction
1.2 Emergence of Nanomedicines
2. PREREQUISITE OF NANOMEDICINES
2.1 Conventional Cancer Treating Approaches
2.2 Nanomedicines: Overcoming the Hurdles
3. DIVERSIFICATION OF NANOMEDICINES
3.1 Classification on Basis of Constituents
3.1.1 Inorganic Nanoparticles
3.1.2 Organic Nanoparticles
3.2 Classification on Basis of Applicability
3.2.1 Nanomedicine as Diagnostic Agents
3.2.2 Nanomedicine as Therapeutic Agents
3.2.3 Nanomedicine as Drug Delivery Agents
3.3 Classification on Basis of Dimensions
4. MECHANISM OF ACTION OF NANOMEDICINE
4.1 Targeting Tumor Cells
4.1.1 Passive Targeting
4.1.2 Active Targeting
4.2 Nanocarrier - Drug Complex
4.2.1 Liposomes
4.2.2 Dendrimers
4.2.3 Micelles
4.2.4 Inorganic Nanocarriers
4.3 Drug Release Systems
5. NANOMEDICINE ENGINEERING: DESIGN & STRATEGY
5.1 Organic Nanoparticles as Nanomedicines
5.1.1 Polymeric Nanoparticle
5.1.2 Lipid Organic Nanoparticles
5.2 Inorganic Nanoparticles as Nanomedicines
5.2.1 Synthesis of Gold Nanoparticle
6. CANCER NANOMEDICINE AS DIAGNOSTIC TOOL
6.1 Detection of Cancer Biomarkers
6.1.1 Detection of Circulating Tumor Cell
6.2 Diagnostic Device & Nanoprobes
6.2.1 Biosensors
6.2.2 Microarrays
6.3 Quantum Dots for Early Cancer Detection
6.3.1 Detection of primary Cancers
6.3.2 Quantum Dots for Tumor Imaging
7. CANCER THERAPEUTICS WITH NANOMEDICINES
7.1 Nanomedicine as Therapeutic Agents
7.1.1 Photodynamic Therapy
7.1.2 Photo Thermal Therapy
7.2 Nanomedicines as Prophylactic & Therapeutic Approach
7.2.1 Cancer Cell Destruction
7.3 Nanomedicine in Breast Cancer
7.4 Nanomedicine in Pancreatic Cancer
7.5 Nanomedicine in Brain Cancer
7.6 Nanomedicine in Lung Cancer
8. CANCER IMAGING WITH NANOMEDICINE
8.1 Positron Emission Tomography
8.1.1 Applications in various Cancers
8.2 Single Photon Emitted Tomography
8.2.1 Computed Tomography
8.3 Magnetic Resonance Imaging (MRI)
8.3.1 Optical Imaging
9. DRUG DELIVERY WITH NANOMEDICINES
9.1 Nanocarrier & Chemotherapy
9.1.1 Peptide Nanomedicine- An Example of Nanocarrier Chemotherapy
9.2 Nanomedicine Endocytosis & Intracellular Mechanisms
9.3 Factors Affecting Drug Delivery
10. GLOBAL CANCER NANOMEDICINE MARKET OVERVIEW
10.1 Current Market Scenario
10.2 Global Cancer Nanomedicine Clinical Pipeline Overview
11. GLOBAL NANOMEDICINE MARKET DYNAMICS
11.1 Encouraging Market Aspects
11.2 Commercialization Challenges
12. GLOBAL CANCER NANOMEDICINE FUTURE PROSPECT
13. GLOBAL CANCER NANOMEDICINE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
13.1 Research
13.2 Preclinical
13.3 Phase-I
13.4 Phase-I/II
13.5 Phase-II
13.6 Phase-III
14. MARKETED CANCER NANOMEDICINE CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE
14.1 Doxorubicin Liposomal (Caelyx & Doxil)
14.2 Albumin-Bound Paclitaxel (Abraxane & Coraxane)
14.3 Nilotinib (Tasigna)
14.4 Paclitaxel Polymeric Micelle Formulation (Cynviloq & Genexol-PM)
14.5 Paclitaxel Liposomal
14.6 Vincristine Liposomal (Marqibo)
14.7 Rexin-G
14.8 Paclitaxel Nanoparticle (Nanoxel)
15. COMPETITIVE LANDSCAPE
15.1 Abraxis BioScience
15.2 Access Pharmaceuticals
15.3 Alnylam Pharmaceuticals
15.4 Amgen
15.5 Arrowhead Research
15.6 BIND Therapeutics
15.7 Cadila Healthcare
15.8 Celegen Corporation
15.9 Celsion Corporation
15.10 Genzyme Corporation
15.11 Merck
15.12 NanoCarrier
15.13 Nippon Kayaku
15.14 Nanobiotix
15.15 Novavax
15.16 Pfizer
15.17 Roche
15.18 Samyang
15.19 Sanofi
15.20 Takeda Pharmaceutical
1.1 Introduction
1.2 Emergence of Nanomedicines
2. PREREQUISITE OF NANOMEDICINES
2.1 Conventional Cancer Treating Approaches
2.2 Nanomedicines: Overcoming the Hurdles
3. DIVERSIFICATION OF NANOMEDICINES
3.1 Classification on Basis of Constituents
3.1.1 Inorganic Nanoparticles
3.1.2 Organic Nanoparticles
3.2 Classification on Basis of Applicability
3.2.1 Nanomedicine as Diagnostic Agents
3.2.2 Nanomedicine as Therapeutic Agents
3.2.3 Nanomedicine as Drug Delivery Agents
3.3 Classification on Basis of Dimensions
4. MECHANISM OF ACTION OF NANOMEDICINE
4.1 Targeting Tumor Cells
4.1.1 Passive Targeting
4.1.2 Active Targeting
4.2 Nanocarrier - Drug Complex
4.2.1 Liposomes
4.2.2 Dendrimers
4.2.3 Micelles
4.2.4 Inorganic Nanocarriers
4.3 Drug Release Systems
5. NANOMEDICINE ENGINEERING: DESIGN & STRATEGY
5.1 Organic Nanoparticles as Nanomedicines
5.1.1 Polymeric Nanoparticle
5.1.2 Lipid Organic Nanoparticles
5.2 Inorganic Nanoparticles as Nanomedicines
5.2.1 Synthesis of Gold Nanoparticle
6. CANCER NANOMEDICINE AS DIAGNOSTIC TOOL
6.1 Detection of Cancer Biomarkers
6.1.1 Detection of Circulating Tumor Cell
6.2 Diagnostic Device & Nanoprobes
6.2.1 Biosensors
6.2.2 Microarrays
6.3 Quantum Dots for Early Cancer Detection
6.3.1 Detection of primary Cancers
6.3.2 Quantum Dots for Tumor Imaging
7. CANCER THERAPEUTICS WITH NANOMEDICINES
7.1 Nanomedicine as Therapeutic Agents
7.1.1 Photodynamic Therapy
7.1.2 Photo Thermal Therapy
7.2 Nanomedicines as Prophylactic & Therapeutic Approach
7.2.1 Cancer Cell Destruction
7.3 Nanomedicine in Breast Cancer
7.4 Nanomedicine in Pancreatic Cancer
7.5 Nanomedicine in Brain Cancer
7.6 Nanomedicine in Lung Cancer
8. CANCER IMAGING WITH NANOMEDICINE
8.1 Positron Emission Tomography
8.1.1 Applications in various Cancers
8.2 Single Photon Emitted Tomography
8.2.1 Computed Tomography
8.3 Magnetic Resonance Imaging (MRI)
8.3.1 Optical Imaging
9. DRUG DELIVERY WITH NANOMEDICINES
9.1 Nanocarrier & Chemotherapy
9.1.1 Peptide Nanomedicine- An Example of Nanocarrier Chemotherapy
9.2 Nanomedicine Endocytosis & Intracellular Mechanisms
9.3 Factors Affecting Drug Delivery
10. GLOBAL CANCER NANOMEDICINE MARKET OVERVIEW
10.1 Current Market Scenario
10.2 Global Cancer Nanomedicine Clinical Pipeline Overview
11. GLOBAL NANOMEDICINE MARKET DYNAMICS
11.1 Encouraging Market Aspects
11.2 Commercialization Challenges
12. GLOBAL CANCER NANOMEDICINE FUTURE PROSPECT
13. GLOBAL CANCER NANOMEDICINE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE
13.1 Research
13.2 Preclinical
13.3 Phase-I
13.4 Phase-I/II
13.5 Phase-II
13.6 Phase-III
14. MARKETED CANCER NANOMEDICINE CLINICAL INSIGHT BY COMPANY, INDICATION & PHASE
14.1 Doxorubicin Liposomal (Caelyx & Doxil)
14.2 Albumin-Bound Paclitaxel (Abraxane & Coraxane)
14.3 Nilotinib (Tasigna)
14.4 Paclitaxel Polymeric Micelle Formulation (Cynviloq & Genexol-PM)
14.5 Paclitaxel Liposomal
14.6 Vincristine Liposomal (Marqibo)
14.7 Rexin-G
14.8 Paclitaxel Nanoparticle (Nanoxel)
15. COMPETITIVE LANDSCAPE
15.1 Abraxis BioScience
15.2 Access Pharmaceuticals
15.3 Alnylam Pharmaceuticals
15.4 Amgen
15.5 Arrowhead Research
15.6 BIND Therapeutics
15.7 Cadila Healthcare
15.8 Celegen Corporation
15.9 Celsion Corporation
15.10 Genzyme Corporation
15.11 Merck
15.12 NanoCarrier
15.13 Nippon Kayaku
15.14 Nanobiotix
15.15 Novavax
15.16 Pfizer
15.17 Roche
15.18 Samyang
15.19 Sanofi
15.20 Takeda Pharmaceutical
LIST OF FIGURES
Figure 1-1: Goals of Nanomedicines
Figure 2-1: Advantages of Nanomedicines over Conventional Therapies
Figure 3-1: Various Classes of Nanomedicines
Figure 3-2: Classification of Nanoparticles
Figure 3-3: Classification on Basis of Applicability
Figure 3-4: Dimensional Nanoconstructs
Figure 4-1: Mechanism of Nanomedicine to Destruct Tumor Cells
Figure 4-2: Vasculature of Tumor & Normal Cell
Figure 4-3: Nanoparticle Drug Delivery Benchmark
Figure 4-4: Liposomes as Nanocarriers
Figure 4-5: Structure of Dendrimers
Figure 4-6: Diverse Drug Release Mechanisms
Figure 5-1: Structure of Nanospheres & Nanocapsules
Figure 5-2: Processes Involved in Organic Polymeric Nanoparticles
Figure 5-3: Nanoparticle Production Methods
Figure 5-4: Different Categories of Emulsions
Figure 5-5: Scheme of Different Strategies of Interfacial Polymerization
Figure 5-6: Different Type of Inorganic Nanoparticle
Figure 5-7: Synthesis of Gold Nanoparticles
Figure 6-1: Functioning of Biosensors in Cancer Detection
Figure 6-2: Detection of Cancer Cells with Quantum Dots
Figure 7-1: Cancer Therapeutics with Nanomedicines
Figure 7-2: Cancer Cell Destruction via Nanomedicines
Figure 7-3: Drug Delivery across Blood Brain Barrier
Figure 8-1: Cancer Imaging Via Various Techniques
Figure 9-1: Nanomedicine & Cell Intake Mechanisms
Figure 9-2: Factors Affecting Drug Delivery
Figure 10-1: Global Nanomedicine Market (US$ Billion), 2013-2022
Figure 10-2: Global - Cancer Nanoparticle Pipeline by Phase (%), 2016 till 2022
Figure 10-3: Global - Cancer Nanoparticle Pipeline by Phase (Numbers), 2016 till 2022
Figure 10-4: Global - Cancer Nanoparticle Pipeline by Phase (%),2016 till 2022
Figure 10-5: Global - Cancer Nanoparticle Pipeline by Phase (Numbers), 2016 till 2022
Figure 11-1: Driving Parameters of Nanomedicines
Figure 11-2: Challenges of Nanomedicine Market
Figure 15-1: Arrowhead Research Corporation Clinical Pipeline
Figure 15-2: NanoCarrier Clinical Pipeline
Figure 1-1: Goals of Nanomedicines
Figure 2-1: Advantages of Nanomedicines over Conventional Therapies
Figure 3-1: Various Classes of Nanomedicines
Figure 3-2: Classification of Nanoparticles
Figure 3-3: Classification on Basis of Applicability
Figure 3-4: Dimensional Nanoconstructs
Figure 4-1: Mechanism of Nanomedicine to Destruct Tumor Cells
Figure 4-2: Vasculature of Tumor & Normal Cell
Figure 4-3: Nanoparticle Drug Delivery Benchmark
Figure 4-4: Liposomes as Nanocarriers
Figure 4-5: Structure of Dendrimers
Figure 4-6: Diverse Drug Release Mechanisms
Figure 5-1: Structure of Nanospheres & Nanocapsules
Figure 5-2: Processes Involved in Organic Polymeric Nanoparticles
Figure 5-3: Nanoparticle Production Methods
Figure 5-4: Different Categories of Emulsions
Figure 5-5: Scheme of Different Strategies of Interfacial Polymerization
Figure 5-6: Different Type of Inorganic Nanoparticle
Figure 5-7: Synthesis of Gold Nanoparticles
Figure 6-1: Functioning of Biosensors in Cancer Detection
Figure 6-2: Detection of Cancer Cells with Quantum Dots
Figure 7-1: Cancer Therapeutics with Nanomedicines
Figure 7-2: Cancer Cell Destruction via Nanomedicines
Figure 7-3: Drug Delivery across Blood Brain Barrier
Figure 8-1: Cancer Imaging Via Various Techniques
Figure 9-1: Nanomedicine & Cell Intake Mechanisms
Figure 9-2: Factors Affecting Drug Delivery
Figure 10-1: Global Nanomedicine Market (US$ Billion), 2013-2022
Figure 10-2: Global - Cancer Nanoparticle Pipeline by Phase (%), 2016 till 2022
Figure 10-3: Global - Cancer Nanoparticle Pipeline by Phase (Numbers), 2016 till 2022
Figure 10-4: Global - Cancer Nanoparticle Pipeline by Phase (%),2016 till 2022
Figure 10-5: Global - Cancer Nanoparticle Pipeline by Phase (Numbers), 2016 till 2022
Figure 11-1: Driving Parameters of Nanomedicines
Figure 11-2: Challenges of Nanomedicine Market
Figure 15-1: Arrowhead Research Corporation Clinical Pipeline
Figure 15-2: NanoCarrier Clinical Pipeline
